Melbourne, Australia and Minnesota, United States – May 9, 2016 – Osprey Medical Inc. (ASX: OSP) is pleased to announce the results of the AVERT Clinical Trial as presented at the Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting in Orlando, Florida on May 4, 2016. The results from the 578 patient trial were presented to one of the world’s largest gatherings of heart specialty physicians and professionals, as the first scientific presentation of the meeting.
The presentation highlighted the significance of post-trial analysis directed by the Physician Steering Committee on the CI-AKI co-primary endpoint of the trial.
Post-trial analysis, presented by Program Chair and AVERT Clinical Trial Principal Investigator, Dr Roxana Mehran, showed a significant reduction of CI-AKI in patients with pre-existing stage 3 kidney disease (eGFR 40-60). Using the “standard criteria” for detection of CI-AKI (Serum Creatinine increase of > 0.5mg/dl or > 25%), a per-protocol analysis of 470 patients revealed:
For full access, please click here.
The presentation highlighted the significance of post-trial analysis directed by the Physician Steering Committee on the CI-AKI co-primary endpoint of the trial.
Post-trial analysis, presented by Program Chair and AVERT Clinical Trial Principal Investigator, Dr Roxana Mehran, showed a significant reduction of CI-AKI in patients with pre-existing stage 3 kidney disease (eGFR 40-60). Using the “standard criteria” for detection of CI-AKI (Serum Creatinine increase of > 0.5mg/dl or > 25%), a per-protocol analysis of 470 patients revealed:
For full access, please click here.
